# Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

> **NCT02273752** · PHASE2 · TERMINATED · sponsor: **Emory University** · enrollment: 2 (actual)

## Conditions studied

- Estrogen Receptor-positive Breast Cancer
- Gastrinoma
- Glucagonoma
- HER2-negative Breast Cancer
- Insulinoma
- Mucositis
- Oral Complications
- Pancreatic Polypeptide Tumor
- Progesterone Receptor-positive Breast Cancer
- Recurrent Breast Cancer
- Recurrent Islet Cell Carcinoma
- Recurrent Renal Cell Cancer
- Somatostatinoma
- Stage III Renal Cell Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT02273752
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2017-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02273752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02273752, "Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02273752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*